Literature DB >> 22173703

Esophageal cancer risk is associated with polymorphisms of DNA repair genes MSH2 and WRN in Chinese population.

Ting Li1, Qifeng Suo, Dan He, Wenting Du, Mingming Yang, Xuejiao Fan, Ji Liu.   

Abstract

INTRODUCTION: Normal function of DNA repair system is essential for the removal of damage induced by many kinds of internal and environmental agents. Genetic polymorphisms in DNA repair genes associated with modified repair capacity may be related to the risk of developing esophageal cancer (EC). This article dealt whether single-nucleotide polymorphisms of DNA repair genes MSH2, WRN, and Ku70 potentially contributed to EC susceptibility.
METHODS: A hospital-based case-control study with 117 EC cases and 132 controls in a Chinese population was conducted. We genotyped three single-nucleotide polymorphisms MSH2 c.2063T>G, WRN c.4330T>C, and Ku70 c.-1310 C>G using polymerase chain reaction-based restriction fragment length polymorphism and then performed statistical analysis by calculating the adjusted odds ratios (OR) and 95% confidence intervals (95% CI).
RESULTS: Carriers of the MSH2 c.2063 G allele were at a higher risk of developing EC with the TT genotype as reference (OR = 4.53, 95% CI = 1.92-10.64, 33p = 0.001). Also for WRN c.4330T>C, individuals with at least one C allele (T/C or C/C) had a 2.21-fold increased risk for EC development compared with those who bore the T/T wild-type genotype (OR = 2.21, 95% CI = 1.06-4.59, 33p = 0.035). Moreover, statistically significant variant genotypic interaction was suggested between MSH2 and WRN as a result of a much increased predisposition to EC (33p = 0.016). No obvious correlation was observed between Ku70 c.-1310 CG and esophageal carcinogenesis (33p > 0.05).
CONCLUSIONS: Our findings indicated that genetic variants in DNA repair pathways may be involved in esophageal tumorigenesis. MSH2 c.2063 G allele and WRN c.4330 C allele, not Ku70 c.-1310 CG, conferred risk for the process of developing EC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22173703     DOI: 10.1097/JTO.0b013e31823c487a

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  8 in total

1.  Quantitative assessment of the association between XRCC6 C1310G polymorphism and cancer risk.

Authors:  Hong Jiang; Yun Lin; Chang-qing Yang; Qi Li; Jinhong Luo; Ying Zhou; Junli Xue; Wei Wei; Yong Gao
Journal:  Tumour Biol       Date:  2012-12-28

Review 2.  Association between the XRCC6 Promoter rs2267437 polymorphism and cancer risk: evidence based on the current literature.

Authors:  Haitao Xu; Peng Zou; Pin Chen; Lin Zhao; Peng Zhao; Ailin Lu
Journal:  Genet Test Mol Biomarkers       Date:  2013-06-08

Review 3.  RecQ Helicase Somatic Alterations in Cancer.

Authors:  Megha K Thakkar; Jamie Lee; Stefan Meyer; Vivian Y Chang
Journal:  Front Mol Biosci       Date:  2022-06-15

4.  Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.

Authors:  Amrita Singh; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Mol Biol Rep       Date:  2018-02-03       Impact factor: 2.316

5.  The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach.

Authors:  Benjamin J Di Pardo; Nathan W Bronson; Brian S Diggs; Charles R Thomas; John G Hunter; James P Dolan
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

Review 6.  Association between the XRCC6 polymorphisms and cancer risks: a systematic review and meta-analysis.

Authors:  Jing Jia; Juan Ren; Dongmei Yan; Long Xiao; Ruifen Sun
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

7.  Different non-synonymous polymorphisms modulate the interaction of the WRN protein to its protein partners and its enzymatic activities.

Authors:  Jean-Philippe Gagné; Sophie Lachapelle; Chantal Garand; Serges P Tsofack; Yan Coulombe; Marie-Christine Caron; Guy G Poirier; Jean-Yves Masson; Michel Lebel
Journal:  Oncotarget       Date:  2016-12-27

8.  Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.

Authors:  Ruofei Yu; Hua Bai; Bingyu Gao; Tangai Li; Xiran He; Pei Zhang; Jie Wang
Journal:  Thorac Cancer       Date:  2020-11-22       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.